Thermo Fisher Scientific Inc. (NYSE:TMO) Holdings Decreased by Rosenbaum Jay D.

Rosenbaum Jay D. cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 44.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,693 shares of the medical research company's stock after selling 1,336 shares during the quarter. Thermo Fisher Scientific makes up about 2.3% of Rosenbaum Jay D.'s holdings, making the stock its 8th biggest holding. Rosenbaum Jay D.'s holdings in Thermo Fisher Scientific were worth $899,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. WCM Investment Management LLC boosted its stake in Thermo Fisher Scientific by 0.3% in the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company's stock worth $527,524,000 after purchasing an additional 2,928 shares in the last quarter. Summa Corp. bought a new position in Thermo Fisher Scientific during the 4th quarter valued at about $418,000. Phoenix Holdings Ltd. lifted its stake in Thermo Fisher Scientific by 21.4% during the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company's stock valued at $4,750,000 after acquiring an additional 1,654 shares during the period. S. R. Schill & Associates lifted its stake in Thermo Fisher Scientific by 106.3% during the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company's stock valued at $816,000 after acquiring an additional 792 shares during the period. Finally, Check Capital Management Inc. CA bought a new position in Thermo Fisher Scientific during the 3rd quarter valued at about $219,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the firm's stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,000 shares of company stock worth $18,486,980. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

TMO traded up $0.68 during trading on Wednesday, reaching $590.80. 871,441 shares of the company traded hands, compared to its average volume of 1,510,454. The firm has a fifty day simple moving average of $576.49 and a 200 day simple moving average of $545.39. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The company has a market cap of $225.52 billion, a P/E ratio of 37.85, a PEG ratio of 2.46 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts' consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.01%.

Analysts Set New Price Targets

Several research firms have issued reports on TMO. The Goldman Sachs Group upped their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a "buy" rating in a research note on Wednesday, April 10th. JPMorgan Chase & Co. increased their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a research note on Thursday, April 25th. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating on the stock in a research note on Thursday, April 25th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a "buy" rating in a research note on Thursday, April 25th. Finally, Royal Bank of Canada increased their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an "outperform" rating in a research note on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average target price of $607.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.